Immunotherapy Combo Boosts Survival in Metastatic Melanoma

byColleen Fleisson August 19, 2023For patients diagnosed with advancedmetastatic melanomathat does not respond to the commonly utilized PD-1 inhibitors, immunotherapy drugs ipi

Updated on: December 19,2023 16

Immunotherapy Combo Boosts Survival in Metastatic Melanoma

byColleen Fleisson August 19, 2023For patients diagnosed with advancedmetastatic melanomathat does not respond to the commonly utilized PD-1 inhibitors, immunotherapy drugs ipi

Updated on:December 19,2023 16

Strategy could remove metastatic traits and drug resistance from lung cancer cells

byThe Korea Advanced Institute of Science and Technology (KAIST)Figure 1. Construction of the mathematical model of the regulatory network to represent the EMT phenotype based on the interaction

Updated on: December 19,2023 10

Strategy could remove metastatic traits and drug resistance from lung cancer cells

byThe Korea Advanced Institute of Science and Technology (KAIST)Figure 1. Construction of the mathematical model of the regulatory network to represent the EMT phenotype based on the interaction

Updated on:December 19,2023 10

Inequities seen in cancer treatment delay in patients with SARS-CoV-2

by Elana GotkineRace and ethnicity and area-level social determinants of health (SDOH) are associated with delayed or discontinued cancer treatment among patients with severe acute respiratory syndrom

Updated on: December 17,2023 10

Inequities seen in cancer treatment delay in patients with SARS-CoV-2

by Elana GotkineRace and ethnicity and area-level social determinants of health (SDOH) are associated with delayed or discontinued cancer treatment among patients with severe acute respiratory syndrom

Updated on:December 17,2023 10

Tumor Profiling Studies Illuminate Nuances Across Malignancies

November 21, 2022Megan HollaschMolecular and immune landscapes for solid tumors are constantly evolving as precision medicine techniques become more sensitive and next-generation sequencing methods ar

Updated on: October 17,2023 205

Tumor Profiling Studies Illuminate Nuances Across Malignancies

November 21, 2022Megan HollaschMolecular and immune landscapes for solid tumors are constantly evolving as precision medicine techniques become more sensitive and next-generation sequencing methods ar

Updated on:October 17,2023 205

HER2+ early breast cancers where shorter-course trastuzumab could be an option

byEuropean Society for Medical OncologyCredit: European Society for Medical OncologyWomen with HER2-positive early breast cancer with small tumours have similar disease-free survival and lower r

Updated on: December 18,2023 17

HER2+ early breast cancers where shorter-course trastuzumab could be an option

byEuropean Society for Medical OncologyCredit: European Society for Medical OncologyWomen with HER2-positive early breast cancer with small tumours have similar disease-free survival and lower r

Updated on:December 18,2023 17

Survival rates high for children, teens with melanoma

by Lori SolomonSurvival rates for children and adolescents with melanomas are high, according to a study published online Dec. 9 in theJournal of the American Academy of Dermatology.Mary-Ann El

Updated on: December 21,2023 9

Survival rates high for children, teens with melanoma

by Lori SolomonSurvival rates for children and adolescents with melanomas are high, according to a study published online Dec. 9 in theJournal of the American Academy of Dermatology.Mary-Ann El

Updated on:December 21,2023 9

Discovery of small molecule Gαq/11 protein inhibitors against uveal melanoma

by Compuscript LtdGraphical abstract:Constitutively activated Gαq/11 proteins drive the vast majority of uveal melanoma (UM). GQ262 effectively combats UM both in vitro and in vivo by targeting Gαq/11

Updated on: December 21,2023 7

Discovery of small molecule Gαq/11 protein inhibitors against uveal melanoma

by Compuscript LtdGraphical abstract:Constitutively activated Gαq/11 proteins drive the vast majority of uveal melanoma (UM). GQ262 effectively combats UM both in vitro and in vivo by targeting Gαq/11

Updated on:December 21,2023 7

Multi-center study sheds light on understudied breast cancer type

byUniversity of PittsburghCredit: Pixabay/CC0 Public DomainA multi-center analysis of patients with invasive lobular carcinoma, or ILC—the second most common histological subtype of invasive bre

Updated on: December 21,2023 8

Multi-center study sheds light on understudied breast cancer type

byUniversity of PittsburghCredit: Pixabay/CC0 Public DomainA multi-center analysis of patients with invasive lobular carcinoma, or ILC—the second most common histological subtype of invasive bre

Updated on:December 21,2023 8

Testing cells for cancer drug resistance

byRuhr-Universitaet-BochumSamir El-Mashtoly (right) and Klaus Gerwert in the lab at Ruhr-Universität Bochum. Credit: Michael SchwettmannBiophysicists at Ruhr-Universität Bochum (RUB) have demons

Updated on: December 18,2023 12

Testing cells for cancer drug resistance

byRuhr-Universitaet-BochumSamir El-Mashtoly (right) and Klaus Gerwert in the lab at Ruhr-Universität Bochum. Credit: Michael SchwettmannBiophysicists at Ruhr-Universität Bochum (RUB) have demons

Updated on:December 18,2023 12

Missing a Rare Cause of Hereditary Cancer

New research fromCedars-Sinai Cancerinvestigators could warrant reconsideration of current screening guidelines to include a poorly recognized cause of Lynch syndrome, the most common caus

Updated on: November 07,2023 8

Missing a Rare Cause of Hereditary Cancer

New research fromCedars-Sinai Cancerinvestigators could warrant reconsideration of current screening guidelines to include a poorly recognized cause of Lynch syndrome, the most common caus

Updated on:November 07,2023 8

International study designed to identify melanoma patients with high-risk disease

byH. Lee Moffitt Cancer Center & Research InstituteMelanoma. Credit: Wikimedia Commons/National Cancer InstituteThe use of additional adjuvant therapy beyond initial treatment has greatly im

Updated on: December 18,2023 11

International study designed to identify melanoma patients with high-risk disease

byH. Lee Moffitt Cancer Center & Research InstituteMelanoma. Credit: Wikimedia Commons/National Cancer InstituteThe use of additional adjuvant therapy beyond initial treatment has greatly im

Updated on:December 18,2023 11

Fixed-Duration Mosunetuzumab Elicits Durable Responses in R/R Follicular Lymphoma

June 27, 2023Kristi RosaFixed-duration treatment with single-agent mosunetuzumab resulted in a high complete response rate by end of treatment in patients with relapsed or refractory follicular lympho

Updated on: October 15,2023 258

Fixed-Duration Mosunetuzumab Elicits Durable Responses in R/R Follicular Lymphoma

June 27, 2023Kristi RosaFixed-duration treatment with single-agent mosunetuzumab resulted in a high complete response rate by end of treatment in patients with relapsed or refractory follicular lympho

Updated on:October 15,2023 258